Can Zepbound Cause Low Blood Pressure? Understanding the Connection

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Zepbound and Mounjaro, activates GLP-1 and GIP receptors throughout your body—including cells that control blood vessel tone and heart rate. Clinical trials show that some patients experience mild to moderate blood pressure reduction, though severe hypotension remains uncommon when treatment is properly monitored.

How Tirzepatide Affects Your Blood Pressure

Tirzepatide works by signaling two hormone receptors—GLP-1R and GIPR—that regulate appetite, glucose metabolism, and cardiovascular function. When these receptors activate in blood vessels and the autonomic nervous system, they can promote vasodilation (widening of blood vessels), which naturally lowers pressure. Additionally, tirzepatide reduces body weight and improves insulin sensitivity, both of which independently lower blood pressure over time. In pivotal clinical trials, systolic blood pressure dropped an average of 4–6 mmHg from baseline, with some patients seeing reductions exceeding 10 mmHg.

The magnitude of blood pressure change depends on your starting blood pressure, baseline weight, kidney function, and whether you take other cardiovascular medications. Patients with existing hypertension or those on blood pressure-lowering drugs face a higher risk of experiencing clinically meaningful drops. PlexusDx requires a baseline blood pressure reading and periodic monitoring throughout your treatment to catch any concerning trends early.

Who Is at Higher Risk for Low Blood Pressure on Tirzepatide

Certain patient profiles carry elevated risk for hypotension during tirzepatide therapy. Patients already treated for high blood pressure—especially those on ACE inhibitors, ARBs, or calcium channel blockers—face the greatest likelihood of excessive pressure reduction. Older adults, those with chronic kidney disease, patients who are severely dehydrated, and individuals taking other GLP-1 medications simultaneously are also at increased risk. Genetic variants in the GLP1R gene (such as rs6923761) may influence your receptor sensitivity and overall blood pressure response to tirzepatide.

PlexusDx collects your complete medication history and baseline vitals before prescribing tirzepatide. If you already take antihypertensive drugs, your clinician may recommend baseline blood pressure monitoring at home and dose escalation only after your body adjusts to the medication's cardiovascular effects.

Symptoms of Low Blood Pressure During Treatment

Hypotension typically develops gradually as your body adapts to tirzepatide, but some patients notice acute symptoms shortly after injection. Common warning signs include dizziness or lightheadedness upon standing, blurred vision, fatigue, shortness of breath, chest discomfort, or fainting spells. Mild symptoms like transient dizziness affect roughly 5–10% of users and often resolve within the first two weeks as your cardiovascular system recalibrates. Severe hypotensive episodes—where systolic pressure drops below 90 mmHg—occur in fewer than 2% of clinical trial participants.

If you experience persistent dizziness, chest pain, severe shortness of breath, or loss of consciousness, seek immediate medical attention or call 911. Keep a blood pressure log at home, especially during your first month of treatment, and report trends to your PlexusDx clinician before they become problematic. Early detection allows dose adjustment or medication modification before symptoms escalate.

Managing Blood Pressure While on Tirzepatide

PlexusDx monitors your blood pressure systematically through your treatment journey. Your clinician will request baseline and periodic readings—typically at weeks 2, 4, 8, and 12—to track pressure trends and adjust your tirzepatide dose or other medications accordingly. If tirzepatide causes a clinically meaningful drop and you're also on antihypertensive therapy, your doctor may reduce your blood pressure medication dose rather than stopping tirzepatide, since the weight loss and metabolic improvements it provides often justify modest pressure reductions.

Simple lifestyle measures amplify PlexusDx's safety monitoring: increase fluid and electrolyte intake, avoid prolonged standing or rapid position changes, limit alcohol, and maintain consistent meal timing around injections. These habits stabilize blood volume and prevent orthostatic (positional) hypotension. Some patients also benefit from compression socks or a brief increase in dietary salt under physician guidance. PlexusDx clinicians can discuss these strategies during your treatment consultations.

Genetic Factors and Your Tirzepatide Response

Your genetic blueprint influences how strongly your body responds to tirzepatide's blood pressure-lowering effects. Variants in the GLP1R gene, particularly rs6923761, correlate with differences in receptor expression and signaling efficiency; some genetic profiles amplify tirzepatide's cardiovascular impact, while others show more modest blood pressure changes. PlexusDx Precision Peptide Genetic Test examines 14 metabolic and cardiovascular pathways—including GLP1R and GIPR variants—to forecast how your body will likely process tirzepatide and adjust your treatment plan accordingly.

Understanding your genetic predispositions allows PlexusDx to recommend a more cautious starting dose or enhanced monitoring schedule if you carry variants associated with stronger receptor activation. This personalization reduces the likelihood of unwanted hypotension while maximizing your weight loss benefit. The test costs $99 as an add-on after your first month of treatment, giving clinicians real data to refine your ongoing protocol.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can tirzepatide cause dangerous drops in blood pressure?

Severe hypotension occurs in fewer than 2% of clinical trial participants, and PlexusDx requires baseline blood pressure screening plus periodic monitoring to catch problems early. Dangerous drops are preventable when your clinician adjusts your dose or other medications based on actual readings. Contact your doctor immediately if you experience chest pain, severe dizziness, or fainting.

What clinical trials studied tirzepatide's blood pressure effects?

The SURPASS and SURMOUNT trials—which led to FDA approval of tirzepatide—documented systolic blood pressure reductions of 4–6 mmHg on average, with some patients seeing 10+ mmHg drops. These reductions typically mirror weight loss and improved insulin sensitivity rather than direct drug toxicity. Longer-term studies confirm that blood pressure improvements persist and often stabilize after the first 8 weeks.

How much does tirzepatide cost at PlexusDx, and is monitoring included?

PlexusDx Compounded Tirzepatide Injection starts at $249/month across all dosage strengths—your dose may need to go up, but your price won't. All plans include clinician oversight, baseline and periodic blood pressure monitoring, and ongoing adjustments to keep you safe. PlexusDx serves all 50 states, requires no insurance, and accepts HSA and FSA funds.

Should I stop my blood pressure medication if tirzepatide lowers my pressure?

Never stop your blood pressure medication without explicit direction from your PlexusDx clinician. Instead, report your home blood pressure readings regularly so your doctor can decide whether to reduce—not eliminate—your antihypertensive dose. Many patients benefit from continuing lower doses of their original medication while tolerating tirzepatide without problems.

How does genetic testing help predict my blood pressure response?

PlexusDx Precision Peptide Genetic Test examines GLP1R and GIPR variants that influence how strongly your cells respond to tirzepatide's signaling. Patients carrying variants linked to heightened receptor activation receive a more conservative starting dose and closer monitoring, reducing hypotension risk while maintaining efficacy. This $99 add-on test, available after your first month, translates genetic data into actionable treatment adjustments.

Related Reading

• Zepbound For High Blood Pressure
• What Are The Genetic Factors For Low Blood Pressure And Effective Management
• Mounjaro For High Blood Pressure
• Liraglutide For High Blood Pressure

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.